Profits At Top 10 Listed Biopharmaceutical Firms In Shanghai And Shenzhen Up 40 Percent
This article was originally published in PharmAsia News
Executive Summary
According to the "Shanghai, Shenzhen 500 Performance Predictions 2010" report jointly released by Sohu Finance and Wistrategy Consulting, the top 10 listed biopharmaceutical companies will secure 15.7 and 40.4 percent growth in operating income and net profits, respectively